Related Experiment Video
Updated: Jun 14, 2025

Ultrasonic Assessment of Myocardial Microstructure
Published on: January 14, 2014
Association between Atherogenic Dyslipidemia and Subclinical Myocardial Injury in the General Population
Nada S Elbadawi1, Moaze H Sobih1, Mai Z Soliman2
1Epidemiological Cardiology Research Center (EPICARE), Department of Medicine, Section on Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
Insights
Atherogenic dyslipidemia, characterized by high triglycerides and low HDL cholesterol, significantly increases the risk of subclinical myocardial injury. This finding underscores the importance of addressing lipid profiles for cardiovascular disease prevention.
Area of Science:
- Cardiology
- Preventive Medicine
- Lipid Metabolism
Background:
- Subclinical myocardial injury (SCMI) is a predictor of adverse cardiovascular disease (CVD) outcomes.
- Identifying risk factors for SCMI is crucial for CVD prevention and management.
- Atherogenic dyslipidemia, defined by high triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C), is a potential risk factor for SCMI.
Purpose of the Study:
- To investigate the association between atherogenic dyslipidemia and SCMI.
- To examine the relationship between different lipid profiles (TG and HDL-C combinations) and SCMI risk.
Main Methods:
- Analysis of 7093 participants from the National Health and Nutrition Examination Survey (NHANES-III).
- Atherogenic dyslipidemia defined as TG ≥ 150 mg/dL and HDL-C < 40 mg/dL (men) or <50 mg/dL (women).
- SCMI assessed using a cardiac infarction injury score (CIIS) ≥ 10 on electrocardiography; multivariable logistic regression used for analysis.
Main Results:
- 22.5% of participants had atherogenic dyslipidemia, and 26.3% had SCMI.
- Atherogenic dyslipidemia was linked to a higher prevalence of SCMI (31.2% vs. 23.9%, p < 0.001) compared to normal lipid profiles.
- Multivariable analysis showed atherogenic dyslipidemia had the highest odds of SCMI (OR: 1.31, 95% CI: 1.14-1.52).
Conclusions:
- Atherogenic dyslipidemia is significantly associated with an increased risk of SCMI.
- These findings highlight the role of lipid abnormalities beyond traditional risk factors in subclinical CVD development.
- Targeting atherogenic dyslipidemia may be important for SCMI prevention strategies.
Abstract:
Background: Subclinical myocardial injury (SCMI) is associated with an increased risk of poor cardiovascular disease (CVD) outcomes. Understanding the underlying risk factors for SCMI is crucial for the prevention and management of CVD. We hypothesized that atherogenic dyslipidemia, a combination of high triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C), is associated with an increased risk of SCMI. Methods: This analysis from the third National Health and Nutrition Examination Survey (NHANES-III) included 7093 participants (age 59.3 ± 13.4 years, 52.8% women, and 49.4% White) free of CVD. Atherogenic dyslipidemia was defined as TG ≥ 150 mg/dL and HDL-C < 40 mg/dL in men or <50 mg/dL in women. A validated electrocardiographic-based cardiac infarction injury score (CIIS) ≥ 10 was considered positive for SCMI. Multivariable logistic regression analysis was used to examine the association of different combinations of TG and HDL-C groups, including atherogenic dyslipidemia with SCMI. Results: About 22.5% (n = 1594) of participants had atherogenic dyslipidemia, and 26.3% (n = 1862) had SCMI. Compared to participants with normal TG and normal HDL-C, those with atherogenic dyslipidemia had a higher prevalence of SCMI (31.2% vs. 23.9%, p-value < 0.001). In a multivariable logistic regression model, atherogenic dyslipidemia was associated with the highest odds of SCMI followed by high TG/normal HDL-C, then low HDL-C/normal TG [OR (95% CI): 131 (1.14, 1.52), 1.13 (0.97, 1.33), and 1.01 (0.86, 1.20), respectively). Conclusions: Atherogenic dyslipidemia is associated with a higher risk of SCMI, which highlights the role of nontraditional risk factors in the development of subclinical CVD.
More Related Videos
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
09:06Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
Related Concept Videos
Inflammation
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...